Insulin aspart
- Generic Name
- Insulin aspart
- Brand Names
- Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 116094-23-6
- Unique Ingredient Identifier
- D933668QVX
- Background
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
- Associated Therapies
- -
Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.
- Conditions
- Interventions
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2016-07-29
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 70
- Registration Number
- NCT02685449
- Locations
- 🇵🇱
Medical University, Warsaw, Poland
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 834
- Registration Number
- NCT02670915
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Zaporizhzhia, Ukraine
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT02612844
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 46
- Registration Number
- NCT02594033
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT02568280
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2016-04-22
- Lead Sponsor
- University Hospital, Brest
- Target Recruit Count
- 22
- Registration Number
- NCT02546401
- Locations
- 🇫🇷
CHRU Brest, Brest, France
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1108
- Registration Number
- NCT02500706
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Taoyuan, Taiwan
Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart
- Conditions
- Interventions
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT02462161
- Locations
- 🇺🇸
Wake Forest Baptist Hospital, Winston-Salem, North Carolina, United States
A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 335
- Registration Number
- NCT02453685
- Locations
- 🇦🇪
Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 506
- Registration Number
- NCT02420262
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.